Intranasal drug delivery device

Search documents
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue
Globenewswireยท 2025-07-14 17:56
Core Viewpoint - Branded Legacy Inc. is undergoing significant leadership changes and pursuing a strategic merger to enhance its position in the growing addiction therapeutics sector [1][2][3]. Company Changes - The entire existing management team, including David Oswald and Philip White, has resigned, and Jeffery Robison has been appointed as Interim CEO [2][3]. - Robison is leading negotiations for a major merger with an innovative addiction therapeutics company, with a Letter of Intent submitted and expected to be executed soon [3]. Merger Details - The merger is projected to close within two weeks, pending final agreements and regulatory approvals [3]. - The target company has developed advanced technology for addiction treatment, focusing on naloxone, which is a leading product for opioid overdose reversal [4][5]. Innovative Technology - The target company is revolutionizing intranasal drug delivery with a patented all-in-one naloxone device that simplifies administration and reduces costs [5]. - Their platform allows for nasal administration of compounds that traditional devices cannot deliver, expanding treatment options and improving logistics for cold chain-dependent medications [6][7]. Management Expertise - The incoming management team includes experts with extensive backgrounds in health research, clinical trials, data science, and pharmaceutical sciences [8]. - This team aims to enhance treatment delivery efficiency and accessibility, aligning with Branded Legacy's growth vision [9]. Market Potential - The global addiction treatment market was valued at approximately $9 billion in 2023 and is projected to reach over $16.7 billion by 2033, growing at a CAGR of around 6.6% [10]. - The global naloxone market was valued at approximately $1.07 billion in 2023 and is expected to reach $2.48 billion by 2032, driven by rising opioid addiction rates and advancements in treatment technologies [10]. Financial Projections - The combined entity from the merger projects revenue of $40 million in its first year, driven by innovative technologies and market expansions [9][11].